CWA Asset Management Group LLC Purchases 11,964 Shares of AbbVie Inc. $ABBV

CWA Asset Management Group LLC lifted its position in AbbVie Inc. (NYSE:ABBV) by 16.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 83,604 shares of the company’s stock after buying an additional 11,964 shares during the period. AbbVie comprises 0.7% of CWA Asset Management Group LLC’s holdings, making the stock its 29th largest position. CWA Asset Management Group LLC’s holdings in AbbVie were worth $19,103,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Evolution Wealth Management Inc. acquired a new position in AbbVie in the second quarter valued at about $26,000. Chelsea Counsel Co. acquired a new stake in shares of AbbVie during the third quarter worth about $26,000. Texas Capital Bancshares Inc TX acquired a new stake in shares of AbbVie during the third quarter worth about $31,000. Caitlin John LLC bought a new position in shares of AbbVie during the 3rd quarter valued at about $33,000. Finally, Delos Wealth Advisors LLC bought a new position in shares of AbbVie during the 2nd quarter valued at about $39,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.25% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on ABBV. Royal Bank Of Canada assumed coverage on AbbVie in a research note on Tuesday, February 24th. They set an “outperform” rating and a $260.00 target price for the company. Evercore cut their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Barclays assumed coverage on shares of AbbVie in a report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target for the company. Citigroup lowered their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Finally, Berenberg Bank set a $275.00 price objective on shares of AbbVie in a report on Tuesday, January 20th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Stock Performance

Shares of AbbVie stock opened at $204.34 on Friday. The firm has a market cap of $361.31 billion, a PE ratio of 86.59, a P/E/G ratio of 0.71 and a beta of 0.34. The business’s 50 day simple moving average is $223.09 and its 200 day simple moving average is $224.76. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.4%. AbbVie’s dividend payout ratio is presently 293.22%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie signed a multi‑year collaboration with Alloy Therapeutics to develop a next‑generation antibody discovery platform aimed at hard‑to‑drug immunology targets — a pipeline boost that could support future biologics and reduce reliance on existing blockbusters. Is AbbVie (ABBV) Quietly Rewiring Its Immunology Edge With Alloy’s Antibody Discovery Deal?
• Positive Sentiment: Allergan Aesthetics (an AbbVie company) released global consumer research and is rolling out updated educational and treatment frameworks, reinforcing revenue diversification in aesthetic products and services. Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments
• Neutral Sentiment: The U.S. FDA asked manufacturers of certain Parkinson’s drugs to add seizure‑risk warnings — a classwide safety advisory that may affect companies with Parkinson’s portfolios; AbbVie’s direct exposure is unclear but investors should monitor any label updates. US FDA flags seizure risk with certain Parkinson’s drugs, seeks label warnings
• Neutral Sentiment: Macro/flow note — commentary about defensive ETFs and rotation into dividend/defensive sectors could support demand for large dividend payers like AbbVie, but it’s not a catalyst unique to the company. The Market’s Favorite Active ETF Was Made for This Moment. Is It Delivering?
• Negative Sentiment: Johnson & Johnson’s FDA approval of Icotyde, a once‑daily oral IL‑23 inhibitor, materially raised competitive concerns for AbbVie’s Skyrizi (an injectable IL‑23 product). The market reacted sharply as an oral pill can take share from injectables, driving recent ABBV weakness. ABBV Stock Slides 5%: Is J&J’s Icotyde a Threat to Skyrizi?
• Negative Sentiment: A generic entrant (Milnacipran HCl) for Savella® was launched, signaling ongoing generic pressure on some of AbbVie’s older products and modest revenue risk in pain management categories. Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®
• Negative Sentiment: Short‑term price action: analysts and market pieces highlight a recent pullback and underperformance vs. peers, amplifying volatility as investors re‑price growth assumptions for Skyrizi and the company’s near‑term outlook. AbbVie (ABBV) Declines More Than Market: Some Information for Investors

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.